Injective price prediction: Bearish signals intensify as INJ risks further decline

Traders Union
All News
Crypto
Injective slides 11.16% today to $2.91

Highlights

Injective saw a $2 million institutional buy and Korea University launched its first validator by staking 369,809 INJ following recent mainnet upgrades.
Despite a spike in trading volume to $155.4 million, INJ's market capitalization is around $320 million and the token remains under broad selling pressure.
Technically, INJ trades at $2.91 below all major moving averages, with strong bearish momentum and key resistance at $3.34; further downside towards $2.60 is likely.

Institutional inflow and validator launch as volume surges amid price pressure

Recent mainnet upgrades on Injective were accompanied by a $2 million institutional purchase, and Korea University launched its first enterprise validator by staking 369,809 INJ. Trading volume spiked to $155.4 million, reflecting heightened market activity. Injective’s market capitalization stood at approximately $320 million, though price action has remained under broader selling pressure.

Bearish breakout risk as momentum indicators and resistances align

INJ continues to face broad selling pressure, with the current price of $2.91 trading below all key Moving Averages, including the MA-20 ($3.21), MA-50 ($3.95), and MA-200 ($7.86), signaling that short-, medium-, and long-term trends remain clearly bearish. The Ichimoku Kijun sits at $3.34, which marks immediate resistance above the market. Momentum signals from both the MACD and ADX indicate a persistent bearish trend. The Relative Strength Index and Commodity Channel Index both point to weak momentum without strong oversold signals on the daily chart, while the Stochastic RSI remains neutral. Bull/Bear Power shows a slight tilt toward buyer support on the daily, though all intraday timeframes remain negative and seller-dominated. The Awesome Oscillator aligns with this bearish momentum, reinforcing the overall negative trend. Today, INJ is down 11.16%, having opened lower at $3.08 from a previous close of $3.27, demonstrating a clear downside gap. The current price is near the session’s intraday low of $2.89, reflecting high volatility and persistent pressure following the open, consistent with ongoing bearish momentum.

Sideways trading probable as downside risk outweighs rebound chance

Looking ahead, the expected price range for the next 5 trading days is estimated at $2.60 to $3.20, based on the current price and volatility. There is a very high probability (more than 80%) of further price declines, with a price rebound being less likely in the short term. Baseline scenario: INJ trades sideways within this adjusted corridor, showing limited upward momentum. Bullish scenario: a sustained move above the $3.34 resistance may trigger short-term buying. Bearish scenario: a break below $2.60 could accelerate selling toward new lows.

Viktoras Karapetjanc, expert at Traders Union, sees INJ’s recent upgrades and institutional moves as positive signals for long-term potential. He believes that persistent selling pressure and bearish technicals still dominate the short-term landscape. Long-term fundamentals, such as enterprise validators and strong volume, suggest underlying strength even as price action lags. Karapetjanc remains optimistic about a potential rebound if resistance at $3.34 is cleared. "While short-term weakness is apparent, I see recent institutional interest and network activity as building blocks for eventual recovery in INJ."

Previously it was reported that Injective remains entrenched in a bearish trend, trading below all major moving averages as sustained selling pressure persists despite ecosystem growth and institutional inflows. Momentum indicators—including MACD, ADX, and intraday BBP—confirm strong downside momentum and volatility, with resistance seen near the Ichimoku Kijun at $3.34 and support just above the recent session low.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.